Orchard Therapeutics ORTX shares were trading higher on Friday after the company received a positive CHMP opinion for Libmeldy in early-onset metachromatic leukodystrophy.
Orchard Therapeutics is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States.
Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.
Orchard Therapeutics shares traded up 8.33% to $4.55 on Friday. The stock has a 52-week high of $15.93 and a 52-week low of $3.83.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
